The Technical Analyst
Artelo Biosciences Inc [ARTL]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Artelo Biosciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.77% $1.310
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4.23 mill |
| EPS: | -3.14 |
| P/E: | -0.420 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 3.23 mill |
| Avg Daily Volume: | 0.0150 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.420 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.07x |
| Company: PE -0.420 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.41 (83.90%) $1.099 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.226 - 1.394 ( +/- 6.41%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-28 | Favorito Tamara A | Buy | 2 000 | Stock Option (right to buy) |
| 2024-02-28 | Favorito Tamara A | Buy | 1 083 | Stock Option (right to buy) |
| 2024-02-28 | Favorito Tamara A | Buy | 667 | Stock Option (right to buy) |
| 2024-02-28 | Favorito Tamara A | Sell | 1 083 | Stock Option (right to buy) |
| 2024-02-28 | Favorito Tamara A | Sell | 2 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 16.08 |
| Last 100 transactions |
| Buy: 2 033 762 | Sell: 346 866 |
Forecast:
16:00 - $1.310
Live Trading Signals (every 1 min)
Forecast
1: 15:20 - $1.327
Forecast 2: 16:00 - $1.310
Forecast 3: 16:00 - $1.310
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $1.310 (0.77% ) |
| Volume | 0.0151 mill |
| Avg. Vol. | 0.0150 mill |
| % of Avg. Vol | 100.77 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ARTL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ARTL
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-23 08:30:00 - Press Release
Artelo Biosciences Announces Publication Of Peer-reviewed Article Highlighting Fabp7 As A Promising Novel Target In Cancer Therapy
Provides further evidence of multiple opportunities for development of the fabp inhibitor platform in cancer & other serious conditions provides further evidence of multiple opportunities for development of the fabp inhibitor platform in cancer & other serious conditions
2024-04-22 08:30:00 - Press Release
Artelo Biosciences Ceo To Appear On Benzinga All Access On April 23rd At Approximately 10:50 Am Eastern Time
Solana beach, calif., april 22, 2024 (globe newswire) -- artelo biosciences, inc. (nasdaq: artl) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that gregory d. gorgas, president and chief executive officer of artelo, will be a featured guest on the benzinga all access show.
2024-03-25 08:00:00 - Press Release
Artelo Biosciences Reports Fiscal 2023 Year-end Financial Results And Provides Business Update
Major achievements in 2023 lay the foundation for key upcoming milestones major achievements in 2023 lay the foundation for key upcoming milestones
2024-03-12 09:15:00 - Press Release
Artelo Biosciences Selected As A Finalist In Johnson & Johnson's Innovation Challenge
Art26.12 preclinical dermatology research presented to the immuno-dermatology leadership team at johnson & johnson art26.12 preclinical dermatology research presented to the immuno-dermatology leadership team at johnson & johnson
2024-02-15 09:00:00 - Press Release
Artelo Biosciences To Present At The Winter Wrap-up Microcap Rodeo Conference On February 20th
Solana beach, ca / accesswire / february 15, 2024 / artelo biosciences, inc. (nasdaq:artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it will be participating in the winter wrap-up microcap rodeo conference, which will be held virtually tuesday, february 20th through friday, february 23rd, 2024. gregory d.
Latest News
2024-02-15 09:00:00 - Accesswire
Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th
SOLANA BEACH, CA / ACCESSWIRE / February 15, 2024 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it will be participating in the Winter Wrap-Up MicroCap Rodeo Conference, which will be held virtually Tuesday, February 20th through Friday, February 23rd, 2024. Gregory D.
2023-11-30 09:00:00 - GlobeNewsWire
Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
SOLANA BEACH, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced George Warren, PhD., Principal Scientist at Artelo Biosciences, will be presenting new preclinical data on ART12.11, the Company's proprietary cocrystal of cannabidiol (CBD) and tetremethylpyrazine (TMP), at the 4th Annual Med-Cannabis 2023 conference being held December 4-5, 2023 in Frankfurt, Germany.
2023-11-02 08:30:00 - GlobeNewsWire
Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023
SOLANA BEACH, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that the research group working with Steven Laviolette, Ph.D., Scientific Advisor at Artelo Biosciences and Professor in the Schulich School of Medicine at the University of Western Ontario, Canada, will be presenting at Neuroscience 2023. The conference will be hosted by the Society for Neuroscience and held November 11-15, 2023 at the Walter E. Washington Convention Center in Washington, D.C. Neuroscience 2023 is the world's largest source of emerging news on brain science and health, with 25,000 neuroscience researchers and clinicians expected in attendance.
2023-09-13 08:30:00 - GlobeNewsWire
Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th
SOLANA BEACH, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Professor Saoirse O'Sullivan, Artelo's Vice President of Translational Sciences, will be presenting at the 13th Congress of the European Pain Federation (EFIC) being held September 20-22, 2023 at the HUNGEXPO Exhibition Centre in Budapest, Hungary.
2023-09-05 09:00:00 - GlobeNewsWire
Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th
SOLANA BEACH, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.
2023-07-19 09:00:00 - GlobeNewsWire
Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023
New data demonstrates that ART26.12 works by activating multiple receptors implicated in pain signaling and is able to broadly modify lipids in chemotherapy-induced peripheral neuropathy New data demonstrates that ART26.12 works by activating multiple receptors implicated in pain signaling and is able to broadly modify lipids in chemotherapy-induced peripheral neuropathy
2023-06-07 08:30:00 - GlobeNewsWire
Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium
ART12.11, a Novel and Patented Cocrystal of Cannabidiol, Improves Bioavailability and Efficacy of CBD ART12.11, a Novel and Patented Cocrystal of Cannabidiol, Improves Bioavailability and Efficacy of CBD
2023-02-15 08:30:00 - Accesswire
Artelo Biosciences to Present at MicroCap Rodeo's Annual Winter Wonderland – Best Ideas Virtual Investor Conference on February 22, 2023
SOLANA BEACH, CA / ACCESSWIRE / February 15, 2023 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it has been invited to present at MicroCap Rodeo's Third Annual Winter Wonderland - Best Ideas Virtual Investor conference, which is being held virtually on February 21st - 24th, 2023. Gregory D.
2023-01-26 08:30:00 - GlobeNewsWire
Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd
CEO Gregory Gorgas to discuss developments related to the Company's Cancer Appetite Recovery Study (CAReS)
2022-09-22 09:00:00 - GlobeNewsWire
Artelo Biosciences to Present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29th
SOLANA BEACH, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it will be presenting at the 2022 Ladenburg Thalmann Healthcare Conference being held on September 29, 2022 at the Sofitel Hotel in New York City.